Kelly Faulk, MD
Assistant Professor, Pediatrics-Heme/Onc and Bone Marrow Transplantation

Photo
Medical School:
  • MD, University of Colorado Denver School of Medicine (2012)
Graduate School :
  • MSCS, University of Colorado Health Sciences Center (2019)
Undergraduate School:
  • BA, University of Colorado - Boulder (CO) (2007)
Internship:
  • University of Colorado (Children's Hospital Colorado) Program (2012)
Residency:
  • University of Colorado (Children's Hospital Colorado) Program, Pediatrics (2015)
Fellowships:
  • University of Colorado (Children's Hospital Colorado) Program, Pediatric Hematology / Oncology (2018)
  • University of Colorado (Children's Hospital Colorado) Program, Experimental Therapeutics (2019)
Languages: English
Department: Pediatrics-Heme/Onc and Bone Marrow Transplantation

Professional Titles

  • Instructor

Publications

  • Faulk KE, Kairalla JA, Dreyer ZE, Carroll AJ, Heerema NA, Devidas M, Carroll WL, Raetz EA, Loh ML, Hunger SP, Borowitz M, Wang C, Guest E, Brown PA. Minimal residual disease predicts outcomes in KMT2A-rearranged but not KMT2A-germline infant acute lymphoblastic leukemia: report from Children’s Oncology Group study AALL0631. Pediatric Blood and Cancer 2023; 70:e30467. https://doi.org/10.1002/pbc_30467.
  • Zarnegar-Lumley S, Karol SE, Pounds S, Klco JM, Luisa Sulis M, Kuo DJ, Heym KM, Ludwig K, Stevens AM, Alexander TB, Faulk KE, Sabnis HS, Tasian SK, Taub J, Place AE, Rubnitz JE. Preliminary Safety and Efficacy of Venetoclax and Selinexor in Combination with Chemotherapy in Pediatric and Young Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia: SELCLAX. American Society of Hematology (ASH), San Diego, CA, December 2023. Oral Presentation.
  • Faulk K, Kairalla J, Devidas M, Hibbitts E, Carroll A, Heerema N, Kubaney H, August A, Pauly M, Wechsler D, Miles R, Reid J, Druley T, Kihei C, Gore L, Raetz E, Hunger S, Loh M, Brown P, Guest E. Pegaspargase levels in infants with ALL: A report from the Children’s Oncology Group trial AALL15P1. International Society of Paediatric Oncology (SIOP), Barcelona, Spain, September 2022. Poster Presentation.
  • Faulk K, Kairalla J, Devidas M, Hibbitts E, Carroll A, Heerema N, Kubaney H, August A, Pauly M, Wechsler D, Miles R, Reid J, Druley T, Kihei C, Gore L, Raetz E, Hunger S, Loh M, Brown P, Guest E. Pegaspargase levels in infants with ALL: A report from the Children’s Oncology Group trial AALL15P1. The American Society of Pediatric Hematology/Oncology (ASPHO), Pittsburgh, PA, May 2022. Poster Presentation.
  • Lamble A, Yeuh-Yun C, Verma A, Faulk K, Stevens A, Pommert L, Tucker S, Brookhart B, Shah NN, Brooks C, Mughal T, Cooper T. Phase I Study of Tagraxofusp With or Without Chemotherapy in Pediatric Patients with Relapsed or Refractory CD123-Expressing Hematologic Malignancies: A Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium Trial. American Society of Hematology (ASH), New Orleans, LA, December 2022. Poster Presentation.
  • Faulk KE, Anderson-Mellies A, Cockburn M, Green AL. Assessment of enrollment characteristics for Children’s Oncology Group (COG) upfront therapeutic clinical trials 2004-2015. PLoS One. 2020; 15(4)e0230824.
  • The Safety of SARS-Cov-2 Vaccines in Persons with a Known History of Pegaspargase Allergy: A Single Institution Experience. The Journal of Allergy and Clinical Immunology: In Practice, accepted with revisions.
  • Cheung L, Aya-Bonilla C, Cruickshank M, Chiu S, Keuk V, Anderson D, Chua G-A, Singh S, Oommen J, Ferrari Em Hughes A, Ford J, Kunold E, Hesselman M, Post F, Faulk KE, Breese E, Guest E, Brown P, Loh M, Lock R, Kees U, Jafari R, Malinge S, Kotecha R. Preclinical efficacy of azacitidine and venetoclax for infant KMT2A-rearranged ALL reveals a new therapeutic strategy. Leukemia. In-press, 2022.
View All (8 Total) View Less

Practice Locations

Children's Hospital Colorado Anschutz Medical Campus
13123 East 16th Ave
Aurora, CO 80045
720-777-1234

Hospital Affiliation
  • Children's Hospital Colorado

Specialty Information

Specialties
  • Pediatric Hematology / Oncology, Board Certification
  • Pediatrics, Board Certification
Conditions & Treatments
  • Cancers - Leukemia (Childhood)
  • Cancers
  • Cancers - Pediatric Cancer
Clinical Interests
My clinical interest is in early phase clinical trials and translational research in novel pediatric cancer treatments, with a particular emphasis on high risk pediatric cancers and hematologic malignancies.

General Information

Medical Schools:
  • MD, University of Colorado Denver School of Medicine (2012)
Graduate Schools:
  • MSCS, University of Colorado Health Sciences Center (2019)
Undergraduate Schools:
  • BA, University of Colorado - Boulder (CO) (2007)
Internships:
  • University of Colorado (Children's Hospital Colorado) Program (2012)
Residency Programs:
  • University of Colorado (Children's Hospital Colorado) Program, Pediatrics (2015)
Fellowships:
  • University of Colorado (Children's Hospital Colorado) Program, Pediatric Hematology / Oncology (2018)
  • University of Colorado (Children's Hospital Colorado) Program, Experimental Therapeutics (2019)
Languages: English
Department: Pediatrics-Heme/Onc and Bone Marrow Transplantation
SOM Resources
CU Resources
Contact Us
CU Anschutz
Fitzsimons Building
13001 East 17th Place
Campus Box C290
Aurora, CO 80045

Update My Profile
;